Ga-68-FAPI-46 PET scan for colorectal cancer recurrence with rising CEA
Part of Cancer, Digestive system clinical trials.
This trial tests a new type of PET scan called Ga-68-FAPI-46 to help find if your colorectal cancer has returned when your CEA levels are rising. It might offer a more accurate way to detect recurrence early.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 20 years or older.
- You had surgery for colorectal cancer that aimed to remove all cancer, and you have been cancer-free for at least 6 months.
- Your CEA level is higher than normal (over 5 ng/mL) but not above 13 ng/mL, or it has been rising steadily.
- You are already scheduled for a standard FDG PET scan or have had one recently.
- You can lie still for at least 30 minutes during the scan.
- You have an ECOG performance status of 0, 1, or 2 (meaning you are generally active and able to care for yourself).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new imaging agent called 68Ga-FAPI to see how well it finds rectal cancer and guides treatment. It's for people with new stage II or III rectal cancer who are about to start neoadjuvant therapy (treatment before surgery).
This study uses two types of PET/CT scans (68Ga-FAPI-46 and 18F-FDG) to look for any returning ovarian cancer. The goal is to find recurrence early so you and your doctor can plan the next steps.
This trial tests a new type of PET scan (FAPI-PET) to see if it can better find colon cancer that has spread to lymph nodes or other parts of the body. It may help doctors plan the right treatment for you.
This trial tests a new type of PET scan (Ga68-FAPI-46) to better see if cancer from the colon, rectum, or ovary has spread to the lining of the belly. If you are already scheduled for surgery to remove these cancer spots, this scan may help your doctors plan a more complete operation.
This trial tests a new PET scan drug (18F-FAPI) to see if it can better detect where stomach or esophageal cancer has spread. It may help doctors plan the right treatment for you.
This trial uses two types of PET/CT scans (FDG and FAPI) to better see and track colorectal cancer that has spread to the belly lining (peritoneum). It aims to help doctors choose the best treatment by improving how they detect and monitor the cancer.
Hear when a new Colorectal Cancer Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.